Interactions Between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2017 Apr 21

PMID 28424682

Citations 41

Authors

Bas C Mourik

Erik Lubberts

Jurriaan E M de Steenwinkel

Tom H M Ottenhoff

Pieter J M Leenen

Affiliations

Soon will be listed here.

Abstract

The classical paradigm of tuberculosis (TB) immunity, with a central protective role for Th1 responses and IFN-γ-stimulated cellular responses, has been challenged by unsatisfactory results of vaccine strategies aimed at enhancing Th1 immunity. Moreover, preclinical TB models have shown that increasing IFN-γ responses in the lungs is more damaging to the host than to the pathogen. Type 1 interferon signaling and altered Th17 responses have also been associated with active TB, but their functional roles in TB pathogenesis remain to be established. These two host responses have been studied in more detail in autoimmune diseases (AID) and show functional interactions that are of potential interest in TB immunity. In this review, we first identify the role of type 1 interferons and Th17 immunity in TB, followed by an overview of interactions between these responses observed in systemic AID. We discuss (i) the effects of GM-CSF-secreting Th17.1 cells and type 1 interferons on CCR2 monocytes; (ii) convergence of IL-17 and type 1 interferon signaling on stimulating B-cell activating factor production and the central role of neutrophils in this process; and (iii) synergy between IL-17 and type 1 interferons in the generation and function of tertiary lymphoid structures and the associated follicular helper T-cell responses. Evaluation of these autoimmune-related pathways in TB pathogenesis provides a new perspective on recent developments in TB research.

Citing Articles

From heterogeneity to prognosis: understanding the complexity of tertiary lymphoid structures in tumors.

Wang Y, Zhang D, Huang X, Wu G, Wang C, Li J Mol Biol Rep. 2025; 52(1):197.

PMID: 39903372 DOI: 10.1007/s11033-025-10319-3.

The predictive role of tertiary lymphoid structures in the prognosis and response to immunotherapy of lung cancer patients: a systematic review and meta-analysis.

Liu X, Lv W, Huang D, Cui H BMC Cancer. 2025; 25(1):87.

PMID: 39815237 PMC: 11734324. DOI: 10.1186/s12885-025-13484-7.

Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances.

Zhao L, Jin S, Wang S, Zhang Z, Wang X, Chen Z Signal Transduct Target Ther. 2024; 9(1):225.

PMID: 39198425 PMC: 11358547. DOI: 10.1038/s41392-024-01947-5.

Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study.

Torres T, Chiricozzi A, Puig L, Le A, Marzano A, Dapavo P Am J Clin Dermatol. 2024; 25(2):333-342.

PMID: 38265746 PMC: 10867072. DOI: 10.1007/s40257-024-00845-4.

Inflammatory immune profiles associated with disease severity in pulmonary tuberculosis patients with moderate to severe clinical TB or anemia.

Ashenafi S, Loreti M, Bekele A, Aseffa G, Amogne W, Kassa E Front Immunol. 2024; 14:1296501.

PMID: 38162636 PMC: 10756900. DOI: 10.3389/fimmu.2023.1296501.

References

Slight S, Rangel-Moreno J, Gopal R, Lin Y, Junecko B, Mehra S . CXCR5⁺ T helper cells mediate protective immunity against tuberculosis. J Clin Invest. 2013; 123(2):712-26. PMC: 3561804. DOI: 10.1172/JCI65728. View

Zak D, Penn-Nicholson A, Scriba T, Thompson E, Suliman S, Amon L . A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet. 2016; 387(10035):2312-2322. PMC: 5392204. DOI: 10.1016/S0140-6736(15)01316-1. View

Umemura M, Okamoto-Yoshida Y, Yahagi A, Touyama S, Nakae S, Iwakura Y . Involvement of IL-17A-producing TCR γδ T cells in late protective immunity against pulmonary infection. Immun Inflamm Dis. 2016; 4(4):401-412. PMC: 5134718. DOI: 10.1002/iid3.121. View

Eum S, Kong J, Hong M, Lee Y, Kim J, Hwang S . Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest. 2009; 137(1):122-8. PMC: 2803122. DOI: 10.1378/chest.09-0903. View

Noster R, Riedel R, Mashreghi M, Radbruch H, Harms L, Haftmann C . IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci Transl Med. 2014; 6(241):241ra80. DOI: 10.1126/scitranslmed.3008706. View

Cowan J, Pandey S, Filion L, Angel J, Kumar A, Cameron D . Comparison of interferon-γ-, interleukin (IL)-17- and IL-22-expressing CD4 T cells, IL-22-expressing granulocytes and proinflammatory cytokines during latent and active tuberculosis infection. Clin Exp Immunol. 2012; 167(2):317-29. PMC: 3278699. DOI: 10.1111/j.1365-2249.2011.04520.x. View

Berry M, Graham C, McNab F, Xu Z, Bloch S, Oni T . An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature. 2010; 466(7309):973-7. PMC: 3492754. DOI: 10.1038/nature09247. View

Guenova E, Skabytska Y, Hoetzenecker W, Weindl G, Sauer K, Tham M . IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proc Natl Acad Sci U S A. 2015; 112(7):2163-8. PMC: 4343151. DOI: 10.1073/pnas.1416922112. View

Cooper A, Pearl J, Brooks J, Ehlers S, Orme I . Expression of the nitric oxide synthase 2 gene is not essential for early control of Mycobacterium tuberculosis in the murine lung. Infect Immun. 2000; 68(12):6879-82. PMC: 97793. DOI: 10.1128/IAI.68.12.6879-6882.2000. View

10.

Cruz A, Fraga A, Fountain J, Rangel-Moreno J, Torrado E, Saraiva M . Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med. 2010; 207(8):1609-16. PMC: 2916141. DOI: 10.1084/jem.20100265. View

11.

Griffin G, Newton G, Tarrio M, Bu D, Maganto-Garcia E, Azcutia V . IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol. 2012; 188(12):6287-99. PMC: 3370121. DOI: 10.4049/jimmunol.1200385. View

12.

Von Scheidt B, Leung P, Yong M, Zhang Y, Towne J, Smyth M . Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases. Cancer Res. 2014; 74(9):2412-21. DOI: 10.1158/0008-5472.CAN-13-1646. View

13.

Luan B, Yoon Y, Le Lay J, Kaestner K, Hedrick S, Montminy M . CREB pathway links PGE2 signaling with macrophage polarization. Proc Natl Acad Sci U S A. 2015; 112(51):15642-7. PMC: 4697393. DOI: 10.1073/pnas.1519644112. View

14.

Wilson E, Yamada D, Elsaesser H, Herskovitz J, Deng J, Cheng G . Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science. 2013; 340(6129):202-7. PMC: 3704950. DOI: 10.1126/science.1235208. View

15.

Ivashkiv L, Donlin L . Regulation of type I interferon responses. Nat Rev Immunol. 2013; 14(1):36-49. PMC: 4084561. DOI: 10.1038/nri3581. View

16.

Edwards A, Manickasingham S, Sporri R, Diebold S, Schulz O, Sher A . Microbial recognition via Toll-like receptor-dependent and -independent pathways determines the cytokine response of murine dendritic cell subsets to CD40 triggering. J Immunol. 2002; 169(7):3652-60. DOI: 10.4049/jimmunol.169.7.3652. View

17.

Zitvogel L, Galluzzi L, Kepp O, Smyth M, Kroemer G . Type I interferons in anticancer immunity. Nat Rev Immunol. 2015; 15(7):405-14. DOI: 10.1038/nri3845. View

18.

Stanley S, Johndrow J, Manzanillo P, Cox J . The Type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis. J Immunol. 2007; 178(5):3143-52. DOI: 10.4049/jimmunol.178.5.3143. View

19.

Parkes M, Cortes A, van Heel D, Brown M . Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet. 2013; 14(9):661-73. DOI: 10.1038/nrg3502. View

20.

Boniface K, Bak-Jensen K, Li Y, Blumenschein W, McGeachy M, McClanahan T . Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. 2009; 206(3):535-48. PMC: 2699124. DOI: 10.1084/jem.20082293. View